M. Ashton

发表

New perspectives in lead generation II: Evaluating molecular diversity

J. Mason, M. Ashton, M. Jaye, 1996 .

Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP‐specific phosphodiesterase: comparison with rolipram

M. Ashton, J. Karlsson, M. Foster, 1995, British journal of pharmacology.

18 – Anti-inflammatory Effects of Novel Selective Cyclic Nucleotide Phosphodiesterase Inhibitors

M. Ashton, J. Karlsson, D. Raeburn, 1993 .

Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.

M. Ashton, N. Vicker, J. Karlsson, 1994, Journal of medicinal chemistry.

The absorption, metabolism and excretion of disodium cromoglycate in nine animal species.

G. F. Moss, B. Clark, M. Ashton, 1973, Toxicology and applied pharmacology.

Acyl-CoA:Cholesterol O-acyltransferase (ACAT) inhibitors. 2. 2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT.

M. Ashton, D. Riddell, R. Williams, 1996, Journal of medicinal chemistry.

Heterocyclic analogues of chlorcyclizine with potent hypolipidemic activity.

J. Salmon, M. Ashton, D. Riddell, 1984, Journal of medicinal chemistry.

THE METABOLISM OF 1-NAPHTHYLAMINE AND ITS BEARING ON THE MODE OF CARCINOGENESIS OF THE AROMATIC AMINES.

M. Ashton, D. Clayson, 1963, Acta - Unio Internationalis Contra Cancrum.

RP 73163: A bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor

R. C. Bush, M. Ashton, D. Riddell, 1996 .

RP 70676: A potent systematically available inhibitor of acyl-CoA:cholesterol O-acyl transferase (ACAT)

R. C. Bush, M. Ashton, D. Lythgoe, 1992 .

New perspectives in lead generation I: Discovery of biological targets

J. Mason, M. Ashton, M. Jaye, 1996 .

A new class of selective and potent inhibitors of neuronal nitric oxide synthase.

R. Volkmann, J. Lowe, M. Ashton, 1999, Bioorganic & Medicinal Chemistry Letters.